TRAM2

Across TCGA pan-cancer cohorts, TRAM2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TRAM2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRAM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAM2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where TRAM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.210	0.544	.004	25	view →
UCEC	DFS	Quartile	All	0.744	1.000	.014	8	view →
LSCC	DFS	Tertile	II,III,IV	0.477	0.841	.015	7	view →
CCRCC	DFS	Median	All	1.000	0.839	.028	4	view →
GBM	OS	Quartile	All	0.704	0.928	.019	3	view →
HNSC	OS	Quartile	III,IV	0.849	0.620	.021	3	view →
LUAD	DFS	Median	All	0.924	0.510	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TRAM2–PDAC (DFS)

Open the PDAC breakdown →